These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38876134)

  • 1. Radiotherapy for anti-vascular endothelial growth factor injections for neovascular age-related macular degeneration.
    Ying GS; VanderBeek BL
    Lancet; 2024 Jul; 404(10447):4-5. PubMed ID: 38876134
    [No Abstract]   [Full Text] [Related]  

  • 2. Retreatment interval lengthening achieved in two thirds of eyes with prolonged intensive anti-VEGF therapy for neovascular age-related macular degeneration after switching to faricimab.
    Kenworthy MK; Alexis JA; Ramakrishnan P; Chen FK
    Clin Exp Ophthalmol; 2024 Jul; 52(5):589-591. PubMed ID: 38069616
    [No Abstract]   [Full Text] [Related]  

  • 3. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
    Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System.
    Wykoff CC; Hariprasad SM; Zhou B
    Ophthalmic Surg Lasers Imaging Retina; 2018 Dec; 49(12):913-917. PubMed ID: 30566697
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-world evidence for neovascular age-related macular degeneration: a practical approach.
    Teo KYC
    Eye (Lond); 2023 Jan; 37(1):1-3. PubMed ID: 35804018
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration.
    Gallego-Pinazo R; Figueroa MS; García-Layana A
    Curr Opin Ophthalmol; 2015 May; 26(3):200-5. PubMed ID: 25774961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical utilization of anti-VEGF agents and disease monitoring in neovascular age-related macular degeneration.
    Holekamp NM; Liu Y; Yeh WS; Chia Y; Kiss S; Almony A; Kowalski JW
    Am J Ophthalmol; 2014 Apr; 157(4):825-833.e1. PubMed ID: 24388973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intravitreous anti-vascular endothelial growth factor therapy on choroidal thickness in neovascular age-related macular degeneration using spectral-domain optical coherence tomography.
    Branchini L; Regatieri C; Adhi M; Flores-Moreno I; Manjunath V; Fujimoto JG; Duker JS
    JAMA Ophthalmol; 2013 May; 131(5):693-4. PubMed ID: 23494008
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration in 2022: Same, same but different.
    Fung AT
    Clin Exp Ophthalmol; 2022 Apr; 50(3):270-273. PubMed ID: 35174600
    [No Abstract]   [Full Text] [Related]  

  • 14. Macular atrophy development in neovascular age-related macular degeneration.
    Călugăru D; Călugăru M
    Eur J Ophthalmol; 2022 Jan; 32(1):NP307-NP308. PubMed ID: 32755234
    [No Abstract]   [Full Text] [Related]  

  • 15. Recalcitrant neovascular macular degeneration after anti-VEGF therapy: an ongoing challenge.
    Puliafito CA
    Ophthalmic Surg Lasers Imaging Retina; 2013; 44(2):109. PubMed ID: 23510034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SAVING SIGHT IN NEOVASCULAR AMD.
    Retina; 2020 Jul; 40 Suppl 2():S1-S12. PubMed ID: 32558673
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of wet age-related macular degeneration by ranibizumab in "real life" in France: treatment behaviours and associated visual outcome.
    Souied EH; Cohen SY; de Pouvourville G; Dupeyron G; Latour E; Ponthieux A; Weber M
    Acta Ophthalmol; 2015 Mar; 93(2):e179-80. PubMed ID: 25377519
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice.
    Chong EW; Al-Qureshi SH
    Clin Exp Ophthalmol; 2017 May; 45(4):333-335. PubMed ID: 28618455
    [No Abstract]   [Full Text] [Related]  

  • 19. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
    Solomon SD; Lindsley K; Vedula SS; Krzystolik MG; Hawkins BS
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD005139. PubMed ID: 30834517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.